Cytochrome P450 family 21 subfamily A member 2 (CYP21A2) (CYP21A2)

Cytochrome P450 family 21 subfamily A member 2 (CYP21A2), commonly known as steroid 21-hydroxylase, is a vital microsomal enzyme located in the adrenal cortex that plays a central role in the steroidogenic pathway [1, 2]. It is responsible for the hydroxylation of progesterone into 11-deoxycorticosterone and 17-alpha-hydroxyprogesterone into 11-deoxycortisol, which are essential precursors for the synthesis of aldosterone and cortisol, respectively [1, 3]. Mutations in the CYP21A2 gene lead to 21-hydroxylase deficiency, the most prevalent cause of Congenital Adrenal Hyperplasia (CAH), characterized by impaired production of life-sustaining steroids and a compensatory excess of adrenal androgens [3, 4]. This hormonal imbalance can result in severe clinical manifestations, including life-threatening salt-wasting crises, ambiguous genitalia in newborn females, and rapid somatic growth with premature epiphyseal closure [3, 4]. While traditional management focuses on lifelong hormone replacement therapy, modern drug development is exploring gene therapies and CRH receptor antagonists to more precisely modulate the hypothalamic-pituitary-adrenal axis and reduce the side effects associated with chronic steroid use [5]. Understanding the molecular structure and genetic variability of CYP21A2 is crucial for the diagnosis, management, and development of targeted therapies for patients with adrenal disorders [2, 4].

Other names

Steroid 21-hydroxylase21-hydroxylaseCytochrome P450 21CYP21BP450c21Cytochrome P450, subfamily XXI (steroid 21-hydroxylase, belongs to)CP21

Therapeutic intervention involves gene replacement therapy to restore functional enzyme activity, or more commonly, hormonal replacement therapy to provide the end-products (cortisol and aldosterone) that the deficient enzyme cannot produce, thereby suppressing the compensatory overproduction of androgens [3, 5].